Emerging drugs in Europe

Current Opinion in Psychiatry

Volumn 27, Issue 4, 2014, Pages 243-250

  Papaseit, Esther ^a,b   Farré, Magí ^a,b   Schifano, Fabrizio ^c   Torrens, Marta ^b,d  

^a Human Pharmacology and Clinical Neurosciences Research Group IMIM Hospital Del Mar Medical Research Institute   (United States)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^d HOSPITAL DEL MAR   (Spain)

Author keywords

Bath salts; designer drugs; legal highs; new psychoactive substances; research chemicals

Indexed keywords

3 (1 NAPHTHOYL) 1 PENTYLINDOLE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 METHOXYAMPHETAMINE; 4' METHYLMETHCATHINONE; AMPHETAMINE; CANNABINOID DERIVATIVE; CANNABIS; CATHA EDULIS EXTRACT; CATHINONE; COCAINE; FLUNITRAZEPAM; ILLICIT DRUG; KETAMINE; METHADONE; METHYLONE; N,N DIMETHYLTRYPTAMINE; NEW DRUG; NORPSEUDOEPHEDRINE; OPIATE; PHENETHYLAMINE; PIPERAZINE DERIVATIVE; PSEUDOEPHEDRINE; PSYCHOTROPIC AGENT; TETRAHYDROCANNABINOL; TRYPTAMINE DERIVATIVE; STREET DRUG;

ADVERSE DRUG REACTION; AGITATION; ANXIETY; BODY FLUID; CONVENIENCE SAMPLE; DROWSINESS; DRUG ABUSE; DRUG USE; DYSPNEA; EPIDEMIOLOGY; EUROPE; HALLUCINATION; HANGOVER; HUMAN; HYPERTENSION; MYDRIASIS; MYOCLONUS; NAUSEA; PANIC; PARANOIA; POPULATION; REVIEW; SELF REPORT; SUBSTANCE USE;

EUROPE; HUMANS; PSYCHOTROPIC DRUGS; STREET DRUGS;

EID: 84901826103     PISSN: 09517367     EISSN: 14736578     Source Type: Journal    
DOI: 10.1097/YCO.0000000000000071     Document Type: Review

References (49)

1. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Annual report 2012. The state of the drug problem in Europe. http://www.emcdda.europa. eu/attachements.cfm/att-190854-EN-TDAC12001ENC-.pdf. [Accessed 17 December 2013]
2. United Nations Office on Drugs and Crime (UNODC). The challenge of new psychoactive substances. http://www.unodc.org/documents/scientific/NPS-2013- SMART.pdf. [Accessed 17 December 2013]
3. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). EU drug markets report: a strategic analysis. http://www.emcdda.europa.eu/attachements. cfm/att-194349-EN-Case%20study%203-New%20psycho active%20subst-Final.pdf. [Accessed 17 December 2013]
4. Corazza O, Assi S, Simonato P, et al. Promoting innovation and excellence to face the rapid diffusion of Novel Psychoactive Substances in the EU: the outcomes of the ReDNet project. Hum Psychopharmacol 2013; 28:317-323.
5. Deluca P, Davey Z, Corazza O, Di Furia L, et al. Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project. Prog Neuropsychopharmacol Biol Psychiatry 2012; 39:221-226.
6. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Perspectives on drugs. Controlling new psychoactive substances. http://www.emcdda.europa.eu/attachements.cfm/att-211257-EN-EMCDDA-POD-2013- Controlling%20new%20psychoactive%20substances.pdf. [Accessed 24 March 2014]
7. Van Amsterdam J, Nutt D, van den Brink W. Generic legislation of new psychoactive drugs. J Psychopharmacol 2013; 27:317-324.
8. United Nations Office on Drugs and Crime (UNODC). World Drug Report 2013. http://www.unodc.org/unodc/secured/wdr/wdr2013/World-Drug-Report-2013.pdf. [Accessed 17 December 2013]
9. Mixmag. Global Drug Survey: the results. http://www.mixmag.net/words/fea tures/mixmags-global-drug-survey-the-results. [Accessed 17 December 2013]
10. Winstock AR, Kaar S, Borschmann R. Dimethyltryptamine (DMT): prevalence, user characteristics and abuse liability in a large global sample. J Psycho-pharmacol 2014; 28:49-54.
11. Winstock AR, Barratt MJ. Synthetic cannabis: a comparison of patterns of use and effect profile with natural cannabis in a large global sample. Drug Alcohol Depend 2013; 131:106-111.
12. Gonzalez D, Ventura M, Caudevilla F, et al. Consumption of new psychoactive substances in a Spanish sample of research chemical users. Hum Psycho-pharmacol 2013; 28:332-340.
13. Moore K, Dargan PI, Wood DM, et al. Do novel psychoactive substances displace established club drugs, supplement them or act as drugs of initia tion? The relationship between mephedrone, ecstasy and cocaine. Eur Addict Res 2013; 19:276-282.
14. Wood DM, Greene SL, Dargan PI. Five-year trends in self-reported recreational drugs associated with presentation to a UK emergency department with suspected drug-related toxicity. Eur J Emerg Med 2013; 20:263-267.
15. Yamamoto T, Kawsar A, Ramsey J, et al. Monitoring trends in recreational drug use from the analysis of the contents of amnesty bins in gay dance clubs. QJM 2013; 106:1111-1117.
16. Gurdal F, Asirdizer M, Aker RG, et al. Review of detection frequency and type of synthetic cannabinoids in herbal compounds analyzed by Istanbul Narcotic Department of the Council of Forensic Medicine, Turkey. J Forensic Leg Med 2013; 20:667-672.
17. Caudevilla-Galligo F, Ventura M, Indave Ruiz BI, et al. Presence and composition of cathinone derivatives in drug samples taken from a Drug Test Service in Spain (2010-2012). Hum Psychopharmacol 2013; 28:341-344.
18. van Nuijs AL, Castiglioni S, Tarcomnicu I, et al. Illicit drug consumption estimations derived from wastewater analysis: a critical review. Sci Total Environ 2011; 409:3564-3577.
19. Sedefov R, Gallegos A, Mounteney J, Kenny P. Monitoring novel psychoactive substances: a global perspective. In: Dargan PI, Wood DM, editors. Novel psychoactive substances: classification, pharmacology and toxicology. 1st ed. San Diego: Elsevier; 2013. pp. 29-54.
20. Archer JR, Dargan PI, Hudson S, et al. Analysis of anonymous pooled urine from portable urinals in central London confirms the significant use of novel psychoactive substances. QJM 2013; 106:147-152.
21. Reid MJ, Derry L, Thomas KV. Analysis of new classes of recreational drugs in sewage: synthetic cannabinoids and amphetamine-like substances. Drug Test Anal 2014; 6:72-79.
22. Kankaanpaa A, Ariniemi K, Heinonen M, et al. Use of illicit stimulant drugs in Finland: a wastewater study in ten major cities. Sci Total Environ 2013. [Epub ahead of print]
23. Tuv SS, Krabseth H, Karinen R, et al. Prevalence of synthetic cannabinoids in blood samples from Norwegian drivers suspected of impaired driving during a seven weeks period. Accid Anal Prev 2014; 62:26-31.
24. Kronstrand R, Roman M, Andersson M, et al. Toxicological findings of synthetic cannabinoids in recreational users. J Anal Toxicol 2013; 37:534-541.
25. Cosbey SH, Peters KL, Quinn A, et al. Mephedrone (methylmethcathinone) in toxicology casework: a Northern Ireland perspective. J Anal Toxicol 2013; 37:74-82.
26. Musshoff F, Madea B, Kernbach-Wighton G, et al. Drivingunderthe influence of synthetic cannabinoids ('Spice'): a case series. Legal Med 2014; 128:59-64.
27. Hermanns-Clausen M, Kneisel S, Hutter M, et al. Acute intoxication by synthetic cannabinoids-four case reports. Drug Test Anal 2013; 5:790-794.
28. McQuade D, Hudson S, Dargan PI, et al. First European case of convulsions related to analytically confirmed use of the synthetic cannabinoid receptor agonist AM-2201. Eur J Clin Pharmacol 2013; 69:373-376.
29. Derungs A, Schwaninger AE, Mansella G, et al. Symptoms, toxicities, and analytical results for a patient after smoking herbs containing the novel synthetic cannabinoid MAM-2201. Forensic Toxicol 2013; 31:164-171.
30. Adamowicz P, Zuba D, Sekula K. Analysis of UR-144 and its pyrolysis product in blood and their metabolites in urine. Forensic Sci Int 2013; 233:320-327.
31. Adamowicz P, Gil D, Skulska A, et al. Analysis of MDPV in blood-determination and interpretation. J Anal Toxicol 2013; 37:308-312.
32. Zuba D, Adamowicz P, Byrska B. Detection of buphedrone in biological and nonbiological material-two case reports. Forensic Sci Int 2013; 227:15-20.
33. Eiden C, Mathieu MO, Cathala P, Debruyne D, et al. Toxicity and death following recreational use of 2-pyrrolidino valerophenone. Clin Toxicol (Phila) 2013; 51:899-903.
34. Hill SL, Doris T, Gurung S, et al. Severe clinical toxicity associated with analytically confirmed recreational use of 25I-NBOMe: case series. Clin Toxicol (Phila) 2013; 51:487-492.
35. Chan WL, Wood DM, Hudson S, et al. Acute psychosis associated with recreational use of benzofuran 6-(2-aminopropyl)benzofuran (6-APB) and cannabis. J Med Toxicol 2013; 9:278-281.
36. Wikstrom M, Thelander G, Dahlgren M, et al. An accidental fatal intoxication with methoxetamine. J Anal Toxicol 2013; 37:43-46.
37. Helander A, Beck O, Hagerkvist R, et al. Identification of novel psychoactive drug use in Sweden based on laboratory analysis-initial experiences from the STRIDA project. Scand J Clin Lab Invest 2013; 73:400-406.
38. Grigoryev A, Kavanagh P, Melnik A, et al. Gas and liquid chromatography-mass spectrometry detection of the urinary metabolites of UR-144 and its major pyrolysis product. J Anal Toxicol 2013; 37:265-276.
39. Salomone A, Luciano C, Di Corcia D, et al. Hair analysis as a tool to evaluate the prevalence of synthetic cannabinoids in different populations of drug consumers. Drug Test Anal 2014; 6:126-134.
40. Gottardo R, Sorio D, Musile G, et al. Screening for synthetic cannabinoids in hair by using LC-QTOF MS: a new and powerful approach to study the penetration of these new psychoactive substances in the population. Med Sci Law 2014; 54:22-27.
41. Winstock AR, Barratt MJ. The 12-month prevalence and nature of adverse experiences resulting in emergency medical presentations associated with the use of synthetic cannabinoid products. Hum Psychopharmacol 2013; 28:390-393.
42. Hermanns-Clausen M, Kneisel S, Szabo B, et al. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction 2013; 108:534-544.
43. Arora A, Kumar A, Raza MN. 'Legal high' associated Wallenberg syndrome. BMJ Case Rep 2013; 2013.
44. Smith CD, Williams M, Shaikh M. Novel psychoactive substances: a novel clinical challenge. BMJ Case Rep 2013; 2013.
45. Jebadurai J, Schifano F, Deluca P. Recreational use of 1-(2-naphthyl)-2-(1-pyrrolidinyl)-1-pentanone hydrochloride (NRG-1), 6-(2-aminopropyl)benzo-furan (benzofury/6-APB) and NRG-2 with review of available evidence-based literature. Hum Psychopharmacol 2013; 28:356-364.
46. Rhidian R, Babu A. Acute kidney injury requiring haemodialysis following ingestion of mephedrone. BMJ Case Rep 2013; 2013.
47. Conway N, McGowan D, White D, et al. Urinary retention secondary to mephedrone. BMJ Case Rep 2013; 2013.
48. Jovel A, Felthous A, Bhattacharyya A. Delirium due to intoxication from the novel synthetic tryptamine 5-MeO-DALT. J Forensic Sci 2014; 59:844-846.
49. Papanti D, Schifano F, Botteon G, et al. 'Spiceophrenia': a systematic overview of 'Spice'-related psychopathological issues and a case report. Hum Psychopharmacol 2013; 28:379-389.